Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Cash from Operations (2023 - 2025)

Historic Cash from Operations for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$41.1 million.

  • Zenas BioPharma's Cash from Operations fell 3240.93% to -$41.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.5 million, marking a year-over-year decrease of 6418.67%. This contributed to the annual value of -$119.7 million for FY2024, which is 29200.1% down from last year.
  • Zenas BioPharma's Cash from Operations amounted to -$41.1 million in Q3 2025, which was down 3240.93% from -$41.7 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Cash from Operations ranged from a high of -$15.4 million in Q4 2023 and a low of -$41.7 million during Q2 2025
  • In the last 3 years, Zenas BioPharma's Cash from Operations had a median value of -$34.1 million in 2024 and averaged -$31.9 million.
  • In the last 5 years, Zenas BioPharma's Cash from Operations crashed by 15035.06% in 2024 and then tumbled by 3240.93% in 2025.
  • Over the past 3 years, Zenas BioPharma's Cash from Operations (Quarter) stood at -$15.4 million in 2023, then crashed by 150.35% to -$38.6 million in 2024, then decreased by 6.67% to -$41.1 million in 2025.
  • Its Cash from Operations stands at -$41.1 million for Q3 2025, versus -$41.7 million for Q2 2025 and -$37.1 million for Q1 2025.